Selpercatinib

  • TRADE NAME: Retevmo (Loxo Oncology Inc)
  • INDICATIONS:

    Non-small cell lung cancer; thyroid cancer.

    NOTE: (2020) FDA approved under accelerated approval based on overall response rate and duration of response. Continued approval my be contingent upon verification and description of clinical benefit in confirmatory trial(s). 


  • CLASS: Kinase inhibitor, RET (Rearranged during Transfection) kinase inhibitor
  • HALF-LIFE: 32 hours

FDA APPROVAL DATE: 05/08/2020

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

acid-reducing agents (proton pump inhibitors, H2 receptor antagonists, locally-acting antacids), CYP2C8 and CYP3A substrates, CYP3A inducers, CYP3A inhibitors, Itraconazole, Midazolam, Omeprazole, Repaglinide, Rifampin


Can cause fetal harm. Advise females of reproductive potential of the possible risk to the fetus and to use effective contraception.

Our database has 31 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.


Page last updated 02/10/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top